Physician profile
Martha E Laird
NPI 1730177577
$1,827.57
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $370 · 2021: $590 · 2022: $264 · 2023: $195 · 2024: $29.09.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $224.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $606.67 | 2019-2023 | |
| Therapeuticsmd, INC. | $136.33 | 2019-2021 | |
| Exeltis, USA INC. | $133.30 | 2020-2023 | Slynd |
| Merck Sharp & Dohme LLC | $132.61 | 2019-2021 | |
| Organon LLC | $105.79 | 2021-2023 | Nexplanon |
| Evofem Biosciences, INC. | $92.28 | 2020-2021 | |
| Hologic Sales and Service, LLC | $88.75 | 2021-2023 | Aptima |
| Myovant Sciences INC. | $87.39 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.29 | 2019-2023 | |
| Avion Pharmaceuticals | $65.61 | 2020 | |
| Amag Pharmaceuticals, INC. | $58.33 | 2019 | |
| Astellas Pharma US INC | $45.67 | 2023-2024 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $36.95 | 2023 | Myfembree |
| Millicent US INC | $35.35 | 2020-2021 | |
| Agile Therapeutics, INC. | $27.95 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $23.85 | 2021 | |
| Pfizer INC. | $23.04 | 2019 | |
| Boston Scientific Corporation | $14.99 | 2019 | |
| Allergan, INC. | $11.75 | 2020 | |
| Coopersurgical, INC. | $10.85 | 2019 | |
| Mayne Pharma Commercial LLC | $8.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Laird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.